Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They sure as hell wouldn't have had their employee present their data if it was negative.
Fifty years ago I was doing law enforcement research into best-practices and we had a chance to marry-up IBM electronic records keeping, Motorola in-car communications and Helicopter patrol effectiveness into a single study. Sane story. We had to show a bank account large enough to cover the staffing requirements to get the study off the ground. Our income was guaranteed but would only start to flow on a quarterly basis after the essential equipment was put in place. The financial people wanted to own the company. We offered to double their money,(that would have been virtually guaranteed at the contract signing) they wouldn't budge. The project died and I moved on.
I just hope that this company might remember the small investor if they take it public. Can you do an IPO without the STREET sucking up all the initial profit. I would sure like to get a piece of Secure Supply if the time comes.
I wonder if there any way to discern any reactions to the presentation? The attendees are in position to evaluate what they saw in the NNVC information. I wonder if any of them would opine today that NNVC could be a game changer, or did they see the information and yawn.
Do any of you scholarly people know anyone else in that scientific sector who may have seen the presentation and talked to Dr.Friedrich? Can we find a list of attendees?
Colonel Sanders?. Really? Let's do some research people.
But it's a "testament" of some sort to Gene and his PR machine that NNVC has been able to generate as much conversation as it does for such a small company.
Some background on Dr. Friedrich. I find it encouraging that he will be at a conference with scientists who could easily call him out if the data he represents is bogus. NNVC would hardly take the chance to have him present if they thought they were going to get negative feedback. Why would they take that risk? As illustrated below he knows how to properly present data.
Publications
Potential Vaccines and Post-Exposure Treatments for Filovirus Infections
Viruses
September 2012
Viruses of the family Filoviridae represent significant health risks as emerging infectious diseases as well as potentially engineered biothreats. While many research efforts have been published offering possibilities toward the mitigation of filoviral infection, there remain no sanctioned therapeutic or vaccine strategies. Current progress in the development of filovirus therapeutics and vaccines is outlined herein with respect to their current level of testing, evaluation, and proximity toward human implementation, specifically with regard to human clinical trials, nonhuman primate studies, small animal studies, and in vitro development. Contemporary methods of supportive care and previous treatment approaches for human patients are also discussed.
Authors:
Brian Friedrich, John Trefry, Julia E Biggins, Lisa Hensley, Anna Honko, Darci Smith, Gene Garrard Olinger Jr. , Ph.D. MBA
Assessment of High-Throughput Screening (HTS) Methods for High-Consequence Pathogens
Journal of Bioterrorism & Biodefense
December 2011
Currently, there are no Food and Drug Administration (FDA)- approved antiviral drugs or therapeutics for many of the biosafety level three (BSL-3) and four (BSL-4) pathogens. Many of these high-consequence pathogens, including Venezuelan equine encephalitis virus (VEEV), Ebola virus (EBOV), Marburg virus (MARV), and Lassa virus (LASV), are classified as biothreat agents and the development of therapeutic treatments for these diseases is an important area of research. In recent years, high-throughput screening (HTS) assays have become an effective and robust tool used for drug and therapeutic discovery. There are several types of HTS methods available, including targeted screening, diversity and high-content screening, and RNA interference (RNAi). These screens have been used effectively with a number of BSL-2 pathogens, but present unique challenges for the BSL-3/4 pathogens due to the requirement for higher level biocontainment facilities as well as biosurety requirements. Addressing and overcoming these challenges is essential for the proper adaptation of HTS into higher biocontainment facilities. In this article, we will discuss the advantages and disadvantages of each of the aforementioned HTS methods in the context of BSL-3/4 containment.
Authors:
Brian Friedrich, Corinne E Scully, Jennifer M Brannon, Monica M Ogg, Sara C Johnston, Lisa E Hensley, Gene G Olinger, Darci R Smith
A Functional Role for ADAM10 in Human Immunodeficiency Virus Type-1 Replication
Retrovirology Journal
May 2011
Gene trap insertional mutagenesis was used as a high-throughput approach to discover cellular genes participating in viral infection by screening libraries of cells selected for survival from lytic infection with a variety of viruses. Cells harboring a disrupted ADAM10 (A Disintegrin and Metalloprotease 10) allele survived reovirus infection, and subsequently ADAM10 was shown by RNA interference to be important for replication of HIV-1. Silencing ADAM10 expression with small interfering RNA (siRNA) 48 hours before infection significantly inhibited HIV-1 replication in primary human monocyte-derived macrophages and in CD4? cell lines. In agreement, ADAM10 over-expression significantly increased HIV-1 replication. ADAM10 down-regulation did not inhibit viral reverse transcription, indicating that viral entry and uncoating are also independent of ADAM10 expression. Integration of HIV-1 cDNA was reduced in ADAM10 down-regulated cells; however, concomitant 2-LTR circle formation was not detected, suggesting that HIV-1 does not enter the nucleus. Further, ADAM10 silencing inhibited downstream reporter gene expression and viral protein translation. Interestingly, we found that while the metalloprotease domain of ADAM10 is not required for HIV-1 replication, ADAM15 and ?-secretase (which proteolytically release the extracellular and intracellular domains of ADAM10 from the plasma membrane, respectively) do support productive infection. We propose that ADAM10 facilitates replication at the level of nuclear trafficking. Collectively, our data support a model whereby ADAM10 is cleaved by ADAM15 and ?-secretase and that the ADAM10 intracellular domain directly facilitates HIV-1 nuclear trafficking. Thus, ADAM10 represents a novel cellular target class for development of antiretroviral drugs.
Authors:
Brian Friedrich, James L Murray, Guangyu Li, Jinsong Sheng, Thomas W Hodge, Donald H Rubin, William A O'Brien, Monique R Ferguson
Host factors mediating HIV-1 replication.
Virus Research
August 2011
Human immunodeficiency virus type 1(HIV-1) infection is the leading cause of death worldwide in adults attributable to infectious diseases. Although the majority of infections are in sub-Saharan Africa and Southeast Asia, HIV-1 is also a major health concern in most countries throughout the globe. While current antiretroviral treatments are generally effective, particularly in combination therapy, limitations exist due to drug resistance occurring among the drug classes. Traditionally, HIV-1 drugs have targeted viral proteins, which are mutable targets. As cellular genes mutate relatively infrequently, host proteins may prove to be more durable targets than viral proteins. HIV-1 replication is dependent upon cellular proteins that perform essential roles during the viral life cycle. Maraviroc is the first FDA-approved antiretroviral drug to target a cellular factor, HIV-1 coreceptor CCR5, and serves to intercept viral-host protein-protein interactions mediating entry. Recent large-scale siRNA and shRNA screens have revealed over 1000 candidate host factors that potentially support HIV-1 replication, and have implicated new pathways in the viral life cycle. These host proteins and cellular pathways may represent important targets for future therapeutic discoveries. This review discusses critical cellular factors that facilitate the successive steps in HIV-1 replication
Authors:
Brian Friedrich, Natallia Dziuba, Guangyu Li, Mark Endsley, James Murray, Monique R Ferguson
Quantitative PCR used to Assess HIV-1 Integration and 2-LTR Circle Formation in Human Macrophages, Peripheral Blood Lymphocytes and a CD4+ Cell Line
Virology Journal
December 2010
Integration is an intermediate step in the HIV life cycle and is defined as the insertion of HIV-1 proviral DNA into the host chromosome. If integration does not occur when HIV-1 cDNA enters the nucleus, it circularizes upon itself and forms a 2-LTR circle. Monitoring the level of integrated HIV-1 cDNA in different primary cell subsets is very important in HIV-1 infected individuals. In this study, we utilized a well-defined, sensitive two-step quantitative real-time PCR method to detect HIV-1 integration as well as conventional real-time PCR to detect 2-LTR circle formation in human macrophages and PBL isolated from six different healthy donors, as well as U373 CD4+ cells by infecting with HIV-1SX (R5) or dual-tropic isolate HIV-189.6 (R5/X4) virus strains. We used the FDA-approved integrase inhibitor, raltegravir, to determine quantitative differences of integrated HIV viral cDNA in HIV-1 infected cells with and without raltegravir treatment. Specifically, our results demonstrate that this two-step real-time PCR method can distinguish between HIV-1 integrated viral cDNA and non-integrated nuclear HIV-1 2-LTR circles caused by impaired integration with raltegravir-treatment. This further confirms that only integrated HIV-1 cDNA can be specifically amplified and quantified by two-step PCR without non-specifically detecting non-integrated viral cDNA. These results consistently demonstrate that the well-established real-time PCR assays used are robust, sensitive and quantitative for the detection of HIV-1 integration and 2-LTR circle formation in physiologically relevant human macrophages and PBL using lab-adapted virus strains, instead of pseudovirus. With two-step real-time PCR, we show that unintegrated, nuclear HIV-1 cDNA is not detected in raltegravir-treated cells, while specific for only integrated HIV-1 cDNA in non-treated cells. These methods could be applied as a useful tool in further monitoring specific therapy in HIV-1 infected individuals.
Authors:
Brian Friedrich, Guangyu Li, Natallia Dziuba, Monique R Ferguson
A post-entry role for CD63 in early HIV-1 replication.
Virology
February 2011
Macrophages and CD4+ lymphocytes are the major reservoirs for HIV-1 infection. CD63 is a tetraspanin transmembrane protein, which has been shown to play an essential role during HIV-1 replication in macrophages. In this study, we further confirm the requirement of CD63 in early HIV-1 replication events in both macrophages and a CD4+ cell line. Further analysis revealed that viral attachment and cell-cell fusion were unaffected by CD63 silencing. However, CD63-depleted macrophages showed a significant decrease in the initiation and completion of HIV-1 reverse transcription, affecting subsequent events of the HIV-1 life cycle. Integration of HIV-1 cDNA as well as the formation of 2-LTR circles was notably reduced. Reporter assays showed that CD63 down regulation reduced production of the early HIV protein Tat. In agreement, CD63 silencing also inhibited production of the late protein p24. These findings suggest that CD63 plays an early post-entry role prior to or at the reverse transcription step.
Authors:
Brian Friedrich, Guangyu Li, Natallia Dziuba, James Murray, Monique R. Ferguson
Identification of cellular proteins required for replication of human immunodeficiency virus type 1.
AIDS Res Hum Retroviruses.
April 2012
Cellular proteins are essential for human immunodeficiency virus type 1 (HIV-1) replication and may serve as viable new targets for treating infection. Using gene trap insertional mutagenesis, a high-throughput approach based on random inactivation of cellular genes, candidate genes were found that limit virus replication when mutated. Disrupted genes (N=87) conferring resistance to lytic infection with several viruses were queried for an affect on HIV-1 replication by utilizing small interfering RNA (siRNA) screens in TZM-bl cells. Several genes regulating diverse pathways were found to be required for HIV-1 replication, including DHX8, DNAJA1, GTF2E1, GTF2E2, HAP1, KALRN, UBA3, UBE2E3, and VMP1. Candidate genes were independently tested in primary human macrophages, toxicity assays, and/or Tat-dependent ß-galactosidase reporter assays. Bioinformatics analyses indicated that several host factors present in this study participate in canonical pathways and functional processes implicated in prior genome-wide studies. However, the genes presented in this study did not share identity with those found previously. Novel antiviral targets identified in this study should open new avenues for mechanistic investigation.
Authors:
Brian Friedrich, Natallia Dziuba, Monique R Ferguson, William A O'Brien, James L. Murray, Donald H. Rubin, Natalie J. McDonald, Guangyu Li, Michael W. Shaw, Thomas W. Hodge
Rapid clearance of herpes simplex virus type 2 by CD8+ T cells requires high level expression of effector T cell functions
Journal of Reproductive Immunology
April 2011
Authors:
Brian Friedrich
Supramolecular peptide hydrogel adjuvanted subunit vaccine elicits protective antibody responses against West Nile virus
Vaccine
November 2016
A crucial issue in vaccine development is to balance safety with immunogenicity. The low immunogenicity of most subunit antigens warrants a search for adjuvants able to stimulate both cell-mediated and humoral immunity. In recent years, successful applications of nanotechnology and bioengineering in the field of vaccine development have enabled the production of novel adjuvant technologies. In this work, we investigated totally synthetic and supramolecular peptide hydrogels as novel vaccine adjuvants in conjunction with the immunoprotective envelope protein domain III (EIII) of West Nile virus as an immunogen in a mouse model. Our results indicate that, compared to the clinically approved adjuvant alum, peptide hydrogel adjuvanted antigen elicited stronger antibody responses and conferred significant protection against mortality after virus challenge. The high chemical definition and biocompatibility of self-assembling peptide hydrogels makes them attractive as immune adjuvants for the production of subunit vaccines against viral and bacterial infections where antibody-mediated protection is desirable.
Authors:
Brian Friedrich, Jai Rudra, David Beasley
I get cold sores. The most interesting thing about Abreva is that it is worthless. How they convinced anyone that it was effective is a mystery to me.I use a common OTC triple compound cream to help healing once the sore opens and that is more effective than Abreva.
If we can get the FDA to certify a cream at the same bogus level of Abreva we can apparently make money without proving anything.
I think the Secure Supplies system has tremendous potential and that is why I am long on Coates. Their system's niche is small installs and it would be many years until any impact would be seen on the power grid's systemic problems.
The power grid problem must be solved with a massive infrastructure funding which will put people back to work. The only reason why we haven't done that is political.
U.S. Military operates in areas with lots of burn-off natural gas.
The reason it costs $17,000.00 dollars an hour to fly a helicopter in Afghanistan is that all fuel must be supplied overland through Pakistan by tank truck. (bribes aplenti along the way) Trump's ego will not let him lose Afghanistan. The military needs power in remote places where the natural gas and the hydrogen solutions make sense. Imagine the military deciding to set up a solar unit in every village without power in every god forsaken country we are helping!
George's pipe dream may be taking a reality twist!
This post is too cryptic for me to understand. Are you saying the Coates should be buying back shares?
If the company moves to but back shares does it have to make an immediate announcement? If the principals buy open market shares when do they have to report it?
Yes.
I noted before this process is unproven but apparently somebody with resources believes in Secure Supplies enough to fund their first projects. They could fail.
The other glitch could be that the Coates retrofit of the Cummins does not perform over an extended time period.
So we can still be realistic and keep a critical eye on the future, but both companies are working together to pull off what will be a serious game changer if they succeed.
When Coates re-posted his PR about the Secure Supplies project going forward it caused the spike last week and the boo-birds drove it back down.
Now Secure Supplies is posting on it's web site that the news is genuine. They are referring to the delivery of the Cummins engine to Coates as "their" first engine. And showing pics of their execs with George at his facility.
Now you have to believe that Coates has convinced a private company to help him out with his scam if you want to keep on believing nothing is happening. I'm staying put, 8.5M. I think I am going to be a happy camper soon. Maybe even buy some more.
If they do not have good news from Moffet then the Warrants are the only thing that will allow them to bump the price for another stock issue. Problem is, at this point long time holders may run to the exit if the price rises and defeat the whole idea. An issue limited to 19M is not going to make a difference if it is for pennies.
If it is just a bold faced fraud then they will go to testing anyway and stave off death until the testing fails, so going to testing may not even save the day.
https://securesupplyusa.com/2017/01/secure-supply-usa-green-h2-prime-power-storage-solutions/
Secure Supplies has pictures of their execs at the Coates plant date April 8. I can't get an email reply from them confirming the Coates contract moving forward. If they have a signed deal moving forward with the project you would think that they would support their supplier with a public announcement.
Does anyone have any contacts who can get through to SS? Can we reach them to confirm or deny the Coates deal.
Secure Supplies was presenting to Wall Street last month. I think their idea was just a concept. That said, the purpose of their presenting was to attract investors. Perhaps they were successful.
No offense taken. However, Secure Supplies claimed that the technology they are using has been demonstrated with a smaller engine (Wall Street Presentation). Coates was angry that other companies tried to sell engines to SS after that presentation. I asked SS in an email if they were using the Coates engine and I got no reply (though the engine pictured for sale on their web site looks like the Coates). Now that there is an announcement I am assuming a Coates was the smaller engine they used as their demo.
Of course they could all be lying. But the conspiracy scenario gets more difficult to sustain as more actors join in.
That exchange is true. I have seen it before.
On another note:
It is always funny (ironic) when people argue that a person who they support is not devious but just giving out misinformation from lack of insight. It is supposed to make me happy that they are indeed an idiot, but really a nice guy. (see: Bush43)
We are buying the engine, adapting it and shipping it on. Doesn't take too much capacity to do that and time to gear up for volume is trivial when just doing the refit. Cummins is not going to slow down our supply needs as they are solid. (look here for the buy-out or license to supply this contract by Cummins) If the buyer is really moving then Coates is a slam dunk. The only thing that could kill Coates long term is if the refit does not perform over time. If Cummins buys into the concept then the real money will come from licensing to them and others. Coates does not need to become a giant manufacturer.
8.5M holder and I will probably sell 1-2 M at .10 when we get there and hold the rest.
People I know are going to a doctor near me and he is harvesting stem cells from their stomachs and injecting them in their knees to replace cartilage. The procedure is not covered by insurance because it is an unproven procedure. ($7K upfront)
I am entirely new to biotech but I continue to wonder, What prevents NNVC from selling a cream that has tiny plastic thingies in it and just claiming it will make skin problems like a Shingles outbreak feel better. Put your first product out as a therapeutic relief and if it cures people the cash will flow in and allow the continued development of the claimed series of drugs to cure all.
go to finviz search NNVC this is a copy of part of their chart
Short Ratio 24.03 Perf Half Y -33.94%
Book/sh 0.33 P/B 3.30 EPS next Y - ROA -32.00% Target Price 5.30 Perf Year -53.62%
Cash/sh 0.30 P/C 3.61 EPS next 5Y - ROE -52.10% 52W Range 1.03 - 2.67 Perf YTD 1.87%
So many things in the world of investing is Alice and wonderland. That's not really a cat.
When I started out here I said that a year ago when I first got in to NNVC I did some very basic research and my impression from what I read was that a lot of people were working with similar nano particles but that the problem facing everyone was keeping the formulates intact in solution. I bought on a bet that NNVC might be the people to solve that problem. If not it goes a long way to explaining the delays. Maybe when they make a batch it works wonders but when they come to the lab the next day it is mush.
The relationship with Theracour was explained to me in the beginning (by a cheerleader) as a shield to prevent big pharma from attacking NNVC with a cheap offering below the true value of the ultimate value of the discovery, if indeed the process could be continued for all viruses. Likewise the special voting shares that make a takeover impossible without the Principal's consent. All this is also possible as part of a scenario to deceive.
I still don't get the $5.20 Target Price.
The status information at finviz.com lists 30 employees working for NNVC. More Lies? Apparently the marketplace thinks people work for NNVC.
Can anyone tell me what finviz.com is indicating where they list the "Target Price" of NNVC as $5:20. Target Price is the only category not explained when the help button is activated. (?)
So that is a no. You have never read a 10Q or 10K filed by the Coates company to verify your claims and you have no comment on Secure Supplies promotional material.
Yes, promotional material released by new companies is based on positive spin. Big revelation.
Once again you are talking about PRs that you don't believe.
Do you believe the payments you cited did not occur?
Were they included in SEC filings.
I cited the notation of a payment to Coates in a filed report to the SEC. If you say there is fraud here do you have evidence that this payment never happened?
I provided the web site where another company has announced the activity at Coates (apparently) being in conjunction with their plans to install Coates engines. That company, Secure Supplies, was presenting on Wall Street today to investors interested in alternative energy resources. Was that also faked news?
If you believe the reported payments did not occur and they were reported to the SEC in Quarterly and Annual filings then you have evidence of fraud. Did you report your findings to the SEC?
don't know what web site you are referencing. https://securesupplyusa.com/ has the Coates announcement about the Cummins engine being delivered to Coates for retrofit. The companies must be linked as Coates claims. You do not address the $500K payment. Is that a lie in the filing.
Secure Supplies claims 1MW level installation will occur in 2017. I realize they are hyping hydrogen power hoping to be a player if it does get going, and that the possibility that we are at the point where there is a shift to hydrogen is a reach, but Coates seems to be positioned to be a partner here.
Back to my original observation. Are they projecting without financing in place or are they indeed ready to proceed. If Secure Supplies is showing the Coates progress on their web site and Coates is claiming payments received of the 1MW size unit which they are prepared to retrofit, it appears that honest-to-god manufacturing is taking place.
The 10K says that Renown Power Development, Ltd gave the company $500K. Is this in dispute?
Again: Is this what is being used for operating cash or is stock being issued to cover operations?
The facility is paid for in July 2018.
Last reports I found were late 2016. New quarterlies should be soon.
No one answered about Secure Power. They are advertising Coates engine for sale on their web site. Are they viable?
This was posted on Scott Trade:
Cummins Delivers the First V12 QST30-G4 Industrial Engine to Coates International, Ltd. Headquarters and Plant in New Jersey to be Retrofitted With the Coates Patented CSRV System to Operate on Gaseous Hydrogen for a Solar Energy Company, Secure Supplies USA LLC With Projects in New Jersey, California, Mexico and Other Locations
Tuesday 03/21/2017 07:36 AM ET - GlobeNewsWire via Dow Jones News
Coates must have had enough money to buy the engine. Now it appears he will develop the larger valve system to accommodate the hydrogen requirements for the solar-to-hydrogen system developed by Secure Supplies.
Back in the dark ages of 64k personal computers many entrepreneurs sold VaporWare. Meaning they would advertise a computer program they had not written yet and take orders for it and when the cash came in they would hire programmers and write the program. There was a great deal of criticism toward these people, but a lot of them delivered and got rich doing it.
From what I see the marketing concept of Secure Supplies is a similar format. Production of a stand alone generating system that frees the user from the Grid would save internal energy costs and the additional possibility of selling both excess power and excess hydrogen as a supplier look intriguing. It looks like Coates is now relying on this model succeeding and generating orders for the Coates System as part of the package. At this time what COTE owners should be analyzing is the viability of the Secure Supplies system and whether they have a reasonable chance to promote their system and attain installation contracts. Do they really have contracts in hand to begin installations? If they have really developed a reliable and economical system to do what they are claiming it could be a game changer. Imagine a large urban hospital or a university that could take itself off the grid. Big money. I am not an engineer or a scientist. Does anyone out there have the expertise to evaluate Secure Supplies claims?
I believe the problem is that people just act like human beings. They know how to fix the engines they have and how to turn down valves and rebuild engines. Telling them that the whole idea is to eliminate the need to make that repair is just not within the worldview they have developed in their lives. (I am assuming this is a selling point of the system besides the efficiency) It seems a good idea for Coates to pursue the large scale industrial applications where economy of scale is decided at a corporate level and the novelty issue is dealt with at a lower level after the install. I.e. maintenance and operations people are just forced to incorporate the newness into their lives as part of a job to be done.
I know this is still being kicked around, but Boniuk is an insider with privileged information. If he is taking a personal position that supports the company wouldn't we (the unwashed) assume that a person with six million to kick around is staying in for a reason? The fact that this transaction was forced to occurred at a time when the company is struggling and someone with this much at stake chose to make the transaction as beneficial for the company as possible seems like a positive.
so what is your take on the declining trend in the short position?
Does anyone know what two international conferences are referred to in Gene's post about USAMRIID presentations? Dates? Places?
If it were true that NNVC is an intentional fraud, the perpetrators would be Sociopathic. Sociopaths only care about themselves and have no feelings or concerns for others. That said, as an eyes wide open hopeful investor with a bet down that I can afford to lose, I still find it difficult to comprehend people with this level of educational background building multi-million dollar labs to keep a scam running. And they could just as easily pocketed that money and continue the fraud anyway without the new lab. I believe they are trying but may fail.
On The Shorts: Sixty-Minutes ran a piece on the NYSE leasing preferred physical positions (yes floor space) for servers running EFT algorithms. Several of these servers could be programmed to work in conjunction. MIT Grads are the “Evil Cabal” writing these algorithms. (I suppose they either do that or video games). Their goal is to make micro profits millions of times over. They haven’t the slightest interest in what each entity is producing or not producing, only that it is trading. The algorithms are based on market activity not entity values. If NANO presents an opportunity for profit by shorting the stock, they take advantage of that. If NANO issues a warrant it will puzzle them for about two days until they factor it into the algorithms, if they even bother. Dave is the one who has pointed this out when he describes cross trading that occurs in split-second intervals.Dave is trying to frighten a computer program.